Literature DB >> 26860335

In situ vaccination for the treatment of cancer.

Linda Hammerich1, Nina Bhardwaj1, Holbrook E Kohrt2, Joshua D Brody1.   

Abstract

Vaccination has had a tremendous impact on human health by harnessing the immune system to prevent and eradicate infectious diseases and this same approach might be used in cancer therapy. Cancer vaccine development has been slowed hindered by the paucity of universal tumor-associated antigens and the difficulty in isolating and preparing individualized vaccines ex vivo. Another approach has been to initiate or stimulate an immune response in situ (at the tumor site) and thus exploit the potentially numerous tumor-associated antigens there. Here, we review the many approaches that have attempted to accomplish effective in situ vaccination, using intratumoral administration of immunomodulators to increase the numbers or activation state of either antigen present cells or T cells within the tumor.

Entities:  

Keywords:  Flt3L; TLR agonist; autologous DC; cytokine; in situ vaccine; oncolytic virus; tumor-associated antigen

Mesh:

Substances:

Year:  2016        PMID: 26860335     DOI: 10.2217/imt.15.120

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  35 in total

1.  Cancer Immunotherapy: From local to global.

Authors:  Willem J M Mulder; Sacha Gnjatic
Journal:  Nat Nanotechnol       Date:  2017-09-06       Impact factor: 39.213

Review 2.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

Review 3.  Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination? Vaccination Strategies Based on NK Cell and ILC Memory.

Authors:  Megan A Cooper; Todd A Fehniger; Marco Colonna
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-10-01       Impact factor: 10.005

Review 4.  Trial watch: Dendritic cell-based anticancer immunotherapy.

Authors:  Abhishek D Garg; Monica Vara Perez; Marco Schaaf; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-05-12       Impact factor: 8.110

5.  In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.

Authors:  Matthew J Frank; Patrick M Reagan; Nancy L Bartlett; Leo I Gordon; Jonathan W Friedberg; Debra K Czerwinski; Steven R Long; Richard T Hoppe; Robert Janssen; Albert F Candia; Robert L Coffman; Ronald Levy
Journal:  Cancer Discov       Date:  2018-08-28       Impact factor: 39.397

6.  Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone.

Authors:  Kristian M Koller; Heath B Mackley; Jason Liu; Henry Wagner; Giampaolo Talamo; Todd D Schell; Colette Pameijer; Rogerio I Neves; Bryan Anderson; Kathleen M Kokolus; Carol A Mallon; Joseph J Drabick
Journal:  Cancer Biol Ther       Date:  2016-12-01       Impact factor: 4.742

7.  Combination of Plant Virus Nanoparticle-Based in Situ Vaccination with Chemotherapy Potentiates Antitumor Response.

Authors:  Karin L Lee; Abner A Murray; Duc H T Le; Mee Rie Sheen; Sourabh Shukla; Ulrich Commandeur; Steven Fiering; Nicole F Steinmetz
Journal:  Nano Lett       Date:  2017-06-26       Impact factor: 11.189

Review 8.  Therapeutic cancer vaccines.

Authors:  Mansi Saxena; Sjoerd H van der Burg; Cornelis J M Melief; Nina Bhardwaj
Journal:  Nat Rev Cancer       Date:  2021-04-27       Impact factor: 60.716

9.  In-situ vaccination using focused ultrasound heating and anti-CD-40 agonistic antibody enhances T-cell mediated local and abscopal effects in murine melanoma.

Authors:  Mohit Pratap Singh; Sri Nandhini Sethuraman; Jerry Ritchey; Steven Fiering; Chandan Guha; Jerry Malayer; Ashish Ranjan
Journal:  Int J Hyperthermia       Date:  2019-11       Impact factor: 3.914

Review 10.  Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy.

Authors:  Michael-Joseph Gorbet; Ashish Ranjan
Journal:  Pharmacol Ther       Date:  2019-12-19       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.